



9TH ILANIT/FISEB CONFERENCE – BioMed Track

Translating Your Ideas Into Commercial Opportunities *Taking innovation to the next level*

“Breakthrough discoveries can not change the world if they do not leave the lab” (WYSS Institute)

A unique workshop co-led by 8400 The Health Network and The Israel Innovation Authority (IIA)

- ❖ **If you are a leading PI, passionate scientist or advanced student, concerned that the rich Israeli research is not being translated into commercial impact;**
- ❖ **If you are considering a career path of project leader or already started this journey and wish to learn more;**
- ❖ **If your research could be directly translated into cure and wellbeing - but you don't know just how to maximize the opportunities**

-> this workshop is for you!

Goals and guidelines

1. Leverage the rich experience of Prof. Donald E. Ingber in Translational Science models to educate participants on best practices, and avoiding common pitfalls (<https://wyss.harvard.edu/team/executive-team/donald-ingber/>).
2. Use the opportunity for mutual enrichment between the keynote speaker and our multi-angled Ecosystem leaders' insights.
3. Be exposed to the Bio Convergence opportunity – Israel Innovation Authority IIA's novel strategy for Ecosystem growth.

Workshop Theme

Prof. Donald E. Ingber, founding director and president of the WYSS Institute for Biologically Inspired Engineering, will briefly share some key insights derived from his extensive experience in translating his and others' research into commercial enterprises and the WYSS institute Model. Five HealthTech Ecosystem leaders will briefly share their perspectives (research, corporate executive management, investment, technology transfer) and address questions to Prof. Ingber. Then session participants will break into small discussion groups, in which they will relate their learnings from the speaker and Ecosystem leaders to current issues and dilemmas that they are facing. Each team will report back very briefly to allow Prof. Ingber to briefly respond.





רשות החדשנות
Israel Innovation
Authority



The program details:

Chairs – Adv. Daphna Murvitz (8400), Dr. Ronit Bendori (Evergreen, Ethos)

- Opening - introducing the topic and speaker - 5 min
- Keynote speaker: Prof. Don Ingber - The WYSS Model – 20 min
- Panel – 5 points of view, with participation of Prof. Ingber and:
 - ⊖ **Prof. Rotem Sorek** (Weizmann Institute) - Researcher's view – 5+2 min
 - ⊖ **Dr. Tamar Raz** (Hadasit and an 8400 Network member) - TTO Researcher's view
 - **Dr. Merav Bassan** (BiomX and an 8400 Network member)- The corporate view - 5+2 min
 - **Dr. Aric Orbach** (Teva) - Multinational Perspective - 5+2 min
 - **Dr. Nissim Darwish** (Orbimed) - The Investor view - 5+2 min
- Discussion tables. Each table led by a local industry leader (see below). Participants share their own stories and experiences and discuss how these are related to the learning of speaker and panelists. 20 min
- Share top 7-10 challenges with plenary and speaker. 15 mins
- Closing remarks - **Dr. Itai Kela** (Israel Innovation Authority, IIA, and an 8400 Network member) - Bio Convergence in Israel - 5 min

Discussion tables' leaders (see Ronit table)

Mr. Didi Daboush (MyBiotics Pharma and an 8400 Network member)

Dr. Kfir Oved (Canopy Biotech), **Dr. Leah Klapper** (FutuRx), **Dr. Natalie Yivgi Ohana** (Minovia Therapeutics and an 8400 Network member), **Dr. Nissim Darwish** (OrbiMed), **Dr. Noga Yerushalmi** (M Ventures), **Dr. Tehila Ben Moshe** (Biond Biologics and an 8400 Network member), **Dr. Aric Orbach** (Teva) and others..

